NS0 cells are a model cell line derived from the nonsecreting murine myeloma used in biomedical research and commercially in the production of therapeutic proteins.[1] The cell line is a cholesterol-dependent cell line that was generated from a subline of NSI/1 which produced only the light chain but no heavy chain.[2][3]

Cell line development

Development of murine neoplasms started with work with the BALB/c mice to isolate the IgG1 secreting MOPC21 tumor. From this tumor, the P3K cells were isolated and developed into two cell lines, 289-16 and P3-X63. The 289-16 cell line secreted only light chain and no heavy chain and was renamed NSI/1. Clones from that cell line were isolated and a nonsecreting cell line was identified and was named NS0/1.[2][4]

Uses in biotechnology

As myeloma cells, NSo cells are naturally antibody-producing suspension cells with a lymphoblast morphology.[5] Gene amplification is typically performed using GS-transfected NS0 cells to select for producing cell lines.[6] The GS-NS0 is a heterologous mammalian expression system that allows for the rapid expression of recombinant proteins. Several therapeutic antibody products are produced using the NS0 cell line including daclizumab and eculizumab.[7]

References

  1. ^ Barnes, LM; Bentley, CM; Dickson, AJ (February 2000). "Advances in animal cell recombinant protein production: GS-NS0 expression system". Cytotechnology. 32 (2): 109–23. doi:10.1023/A:1008170710003. PMC 3449689. PMID 19002973.
  2. ^ a b M. Barnes, Louise; Bentley, Catherine M.; Dickson, Alan J. (2000). "Advances in animal cell recombinant protein production: GS-NS0 expression system". Cytotechnology. 32 (2): 109–123. doi:10.1023/A:1008170710003. PMC 3449689. PMID 19002973.
  3. ^ Sato, JD; Cao, HT; Kayada, Y; Cabot, MC; Sato, GH; Okamoto, T; Welsh, CJ (December 1988). "Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium". In Vitro Cellular & Developmental Biology. 24 (12): 1223–8. doi:10.1007/bf02624194. PMID 3209588. S2CID 2470410.
  4. ^ Galfrè, G; Milstein, C (1981). "[1] Preparation of monoclonal antibodies: Strategies and procedures". Preparation of monoclonal antibodies: strategies and procedures. Methods in Enzymology. Vol. 73. pp. 3–46. doi:10.1016/0076-6879(81)73054-4. ISBN 9780121819736. PMID 7300683.
  5. ^ "NS0 Cell Line from murine myeloma". Retrieved 15 July 2018.
  6. ^ Barnes, Louise M.; Bentley, Catherine M.; Dickson, Alan J. (20 May 2001). "Characterization of the stability of recombinant protein production in the GS-NS0 expression system". Biotechnology and Bioengineering. 73 (4): 261–270. doi:10.1002/bit.1059. PMID 11283909.
  7. ^ Wurm, Florian M (November 2004). "Production of recombinant protein therapeutics in cultivated mammalian cells". Nature Biotechnology. 22 (11): 1393–8. doi:10.1038/nbt1026. PMID 15529164. S2CID 20428452.

External links


Categories